Table 4:
MPM assigned categories breakdown of nodule risk prediction. Refer to Supplemental Table A.2 for complete size-based breakdown.
| MPM | Nodule Size | Malignancy probability and associated clinical guidelines for treatment/ nodule evaluation | ||
|---|---|---|---|---|
| MC | < 3% Watchful waiting | 3–68% Needle biopsy | > 68% Surgery | |
| All | 0M: 6B | 61M: 225B | 19M: 6B | |
| 0% malignant wait | 98% benign immediate work-up | |||
| ≥ 8mm to < 15mm | 0M: 0B | 26M: 91B | 1M: 1B | |
| 0% malignant wait | 100% benign immediate work-up | |||
| ≥ 15mm | 0M: 0B | 24M: 24B | 18M: 6B | |
| 0% malignant wait | 100% benign immediate work-up | |||
| VA | < 20% Watchful waiting | 20–69% Needle biopsy | > 69%Surgery | |
| All | 7M: 58B | 51M: 163B | 22M: 16B | |
| 9% malignant wait | 76% benign immediate work-up | |||
| ≥ 8mm to < 15mm | 1M: 13B | 25M: 75B | 1M: 4B | |
| 4% malignant wait | 86% benign immediate work-up | |||
| ≥ 15mm | 3M: 0B | 18M: 18B | 21M: 12B | |
| 7% malignant waits | 100% benign immediate work-up | |||
| BU | < 10% Low risk | ≥ 10% Higher Risk | ||
| All | 20M: 177B | 60M: 60B | ||
| 25% malignant wait | 25% benign extra procedures | |||
| ≥ 8mm to < 15mm | 9M: 61B | 18M: 31B | ||
| 33% malignant wait | 34% benign immediate work-up | |||
| ≥ 15mm | 0M: 1B | 42M: 29B | ||
| 0% malignant wait | 97% benign immediate work-up | |||
| PU |
< 46.3% Nodule considered benign |
≥ 46.3% Nodule considered malignant |
||
| All | 8M: 87B | 72M: 150B | ||
| 10% malignant wait | 63% benign immediate work-up | |||
| ≥ 8mm to < 15mm | 3M: 33B | 24M: 59B | ||
| 7% malignant wait | 64% benign immediate work-up | |||
| > 15mm | 3M: 4B | 39M: 26B | ||
| 7% malignant wait | 87% benign immediate work-up | |||
Definition of abbreviations: MPM – mathematical prediction model; MC – Mayo Clinic; VA – Veteran’s Affairs; BU – Brock University; PU – Peking University; M – malignant; B - benign